Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial

BACKGROUND: A randomized, double-blind, placebo-controlled phase 2b trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine was conducted in patients with resected stage III/IV melanoma. Dendritic cells (DCs) were harvested with and without granulocyte-colony stimulating factor (...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, Alexandra M., Carpenter, Elizabeth L., Clifton, Guy T., Vreeland, Timothy J., Chick, Robert C., O’Shea, Anne E., McCarthy, Patrick M., Kemp Bohan, Phillip M., Hickerson, Annelies T., Valdera, Franklin A., Tiwari, Ankur, Hale, Diane F., Hyngstrom, John R., Berger, Adam C., Jakub, James W., Sussman, Jeffrey J., Shaheen, Montaser F., Yu, Xianzhong, Wagner, Thomas E., Faries, Mark B., Peoples, George E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433518/
https://www.ncbi.nlm.nih.gov/pubmed/36045304
http://dx.doi.org/10.1007/s00262-022-03272-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433518/
https://www.ncbi.nlm.nih.gov/pubmed/36045304
http://dx.doi.org/10.1007/s00262-022-03272-8

Ejemplares similares